BRIDGEBIO PHARMA INC's ticker is and the CUSIP is 10806XAD4. A total of 45 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41,974,462 | – | 55,810,000 | – | 0.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INHERENT GROUP, LP | 39,500,000 | $15,386,396 | 4.59% |
| Athyrium Capital Management, LP | 20,000,000 | $7,753,900 | 3.26% |
| Diameter Capital Partners LP | 43,287,000 | $16,786,915 | 2.61% |
| Affinity Asset Advisors, LLC | 10,000,000 | $3,895,290 | 1.53% |
| DeepCurrents Investment Group LLC | 39,355,000 | $14,590,746 | 0.57% |
| BRAIDWELL LP | 42,294,000 | $16,151,021 | 0.54% |
| Context Capital Management, LLC | 16,458 | $6,285 | 0.46% |
| Aequim Alternative Investments LP | 31,000,000 | $11,838,125 | 0.32% |
| ARISTEIA CAPITAL, L.L.C. | 40,816,000 | $15,586,610 | 0.31% |
| ABSOLUTE INVESTMENT ADVISERS, LLC | 5,000,000 | $1,875,000 | 0.28% |